{"id":112007,"title":"Angle PLC ( AIM:AGL OTCQX:ANPCY) Breakthrough clinical results","publisher":"Share Talk","author":"sharetalk","published":"2024-01-04T08:17:06+00:00","modified":"2024-01-04T08:32:40+00:00","canonical_url":"https://www.share-talk.com/angle-plc-aimagl-otcqxanpcy-breakthrough-clinical-results/","markdown_url":"https://www.share-talk.com/angle-plc-aimagl-otcqxanpcy-breakthrough-clinical-results.md","json_url":"https://www.share-talk.com/angle-plc-aimagl-otcqxanpcy-breakthrough-clinical-results.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["AGL","Andrew Newland","Angle PLC","breast","Cancer","diagnostics","DNA","DNA molecular","Dr. Karen Miller","liquid biopsy","lung cancer","tumour"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2024/01/AGL.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"**ANGLE PLC (AIM: AGL, OTCQX: ANPCY),** a specialist in liquid biopsy, announced a significant advancement in cancer diagnostics, offering more personalized and actionable insights into the disease and its progression.\n\nThe company has enhanced its Parsortix system to include DNA molecular analysis. This development enables comprehensive analysis of circulating tumour cells (CTCs) and cell-free tumour DNA (ctDNA) from a single blood sample.\n\nIn a study with 47 patients suffering from breast, lung, prostate, and ovarian cancers, ANGLE’s enhanced technology was able to detect crucial DNA mutations in CTCs, which were not found in ctDNA. Notably, these mutations are relevant to FDA-approved cancer treatments but were overlooked by standard ctDNA analysis.\n\nThe study showed that in 70% of breast and lung cancer cases, and 60% of ovarian cancer cases, actionable DNA variants were present in CTCs but absent in ctDNA. This underscores the potential of ANGLE’s technology in offering a more comprehensive view of cancer progression and therapeutic options.\n\nThis breakthrough could have extensive implications. It allows oncologists to track cancer evolution through regular blood tests by analyzing both CTC-DNA and ctDNA. This method could lead to better-informed treatment decisions, enhanced monitoring of treatment efficacy, early detection of drug resistance, and prompt identification of disease progression.\n\nDr. Karen Miller, ANGLE’s Chief Scientific Officer, emphasized the Parsortix system’s capability to provide optimal samples for analysis, enabling DNA profiling of both living CTCs and ctDNA from deceased cells. She expressed excitement over the discovery of additional variants in CTCs not found in ctDNA, offering more information for clinicians to base treatment decisions.\n\nANGLE is now focusing on the commercialization of these findings. The company aims to provide its advanced DNA molecular solutions to pharmaceutical services clients, capitalizing on its system’s comprehensive analysis capabilities.\n\nConcurrently, ANGLE is collaborating with leading experts and clinicians to promote the clinical adoption of this integrated molecular profiling method. This involves establishing the technology’s performance in analytical settings and proving its efficacy through well-structured clinical trials.\n\nAndrew Newland, ANGLE’s Chief Executive, highlighted the significance of this breakthrough following FDA clearance, demonstrating the clinical value of Next-Generation Sequencing (NGS) molecular analysis of living cancer cells from patient blood samples. He expressed pride in the ANGLE team for this achievement, emphasizing their commitment to transforming cancer patient care through a simple blood test."}